This product is carrier-free and does not contain glycerol, gelatin, or serum albumin. The antibody has not been tested for the suitability in Hyperion imaging application. The end-user will have to determine the suitability.
MABC539
Anti-SFRP2 Antibody, clone 80.8.6, azide free
clone 80.8.6, from mouse
Sinonimo/i:
Secreted frizzled-related protein 2, FRP-2, sFRP-2, Secreted apoptosis-related protein 1, SARP-1
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
100 μG
CHF 680.00
Scegli un formato
Cambia visualizzazione
100 μG
CHF 680.00
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
mouse
Livello qualitativo
Forma dell’anticorpo
purified antibody
Tipo di anticorpo
primary antibodies
Clone
80.8.6, monoclonal
Reattività contro le specie
human
tecniche
immunohistochemistry: suitable
inhibition assay: suitable
Isotipo
IgG2aκ
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
wet ice
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... SFRP2(6423)
Descrizione generale
Secreted frizzled-related proteins (SFRPs) may play a critical role in carcinogenesis by inhibiting the Wnt/beta-catenin signaling pathway. Secreted frizzled-related protein 2 (SFRP2) may be useful to further investigate mammary tumorigenesis as its expression increases with tumor progression in canine mammary gland tumors. SFRP2 in mouse embryos has been found to cause severe shortening of the thoracic region. Studies have shown that this protein is the essential stem cell paracrine factor that is thought to regulate myocardial survival and repair damage in the aftermath of an ischemic injury.
Immunogeno
Epitope: NTR domain
Linear peptide corresponding to the NTR domain of human SFRP2.
Applicazioni
Anti-SFRP2 Antibody, clone 80.8.6, azide free is an antibody against SFRP2 for use in IHC & inhibition.
Inhibition Assay Analysis: Anti-SFRP2, clone 80.8.6 inhibits tube formation and cell migration in vitro on SVR angiosarcoma cells, inhibits angiosarcoma and breast cancer growth in vivo, and increases nuclear NFATc3 levels.
Qualità
Evaluated by Immunohistochemistry in human prostate and human breast cancer tissue.
Imunnohistochemistry Analysis: A 1:500 dilution of this antibody detected SFRP2 in human prostate and human breast cancer tissue.
Imunnohistochemistry Analysis: A 1:500 dilution of this antibody detected SFRP2 in human prostate and human breast cancer tissue.
Descrizione del bersaglio
33 kDa calculated
Stato fisico
Format: Purified
Altre note
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
12 - Non Combustible Liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Amanpreet Kaur et al.
Nature, 532(7598), 250-254 (2016-04-05)
Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis than young. This may be due to accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. However, the effects of the aged microenvironment
Mitchell E Fane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(21), 5709-5719 (2020-10-25)
Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated that both angiogenesis and metastasis are increased in older individuals, and
Y Sun et al.
Oncogene, 35(33), 4321-4334 (2016-01-12)
Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME
-
Our department is interested in your anti-SFRP antibody (MABC539). We would like to use it for Hyperion imaging. Hence, the antibody has to be glycerol free, BSA free, gelatine free, carrier free and unconjugated. Is the antibody presented in 100% PBS?
1 answer-
Helpful?
-
Active Filters
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
